Form 4 Filing for Apogee Therapeutics, Inc.

Michael Thomas Henderson, Chief Executive Officer and Director of Apogee Therapeutics, Inc. (APGE), reported the sale of 17,800 shares of Common Stock on April 8, 2026, under a Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $82.48, with individual transactions ranging from $82.00 to $82.97. Following this transaction, Henderson directly owns 1,135,187 shares. He also reported the sale of 2,000 shares at a weighted average price of $83.26 (ranging from $83.00 to $83.50) and 200 shares at $85.00 on the same date. These transactions are part of the same trading plan, and Henderson has undertaken to provide full information on specific prices upon request. The total number of shares owned after these transactions is 1,132,987.